Investigating miRNA-661 and ATG4-B mRNA expression as potential biomarkers for hepatocellular carcinoma
MA Ali, M Matboli, N El-Khazragy, O Saber… - Biomarkers in …, 2018 - Future Medicine
Biomarkers in Medicine, 2018•Future Medicine
Aim: We aimed to examine the statistical association between serum expression of miRNA
661 (miR-661) and ATG-4B mRNA and hepatocellular carcinoma (HCC) based on in silico
data analysis followed by clinical validation. Patients & methods: Quantitative reverse-
transcriptase real-time PCR was used to examine the expression of miR-661 and ATG-4B
mRNA in the sera of HCC patients versus control. Results: The expression of miR-661 and
ATG-4B mRNA was positive in 97.14 and 77.14%, respectively, in HCC patients. The …
661 (miR-661) and ATG-4B mRNA and hepatocellular carcinoma (HCC) based on in silico
data analysis followed by clinical validation. Patients & methods: Quantitative reverse-
transcriptase real-time PCR was used to examine the expression of miR-661 and ATG-4B
mRNA in the sera of HCC patients versus control. Results: The expression of miR-661 and
ATG-4B mRNA was positive in 97.14 and 77.14%, respectively, in HCC patients. The …
Aim
We aimed to examine the statistical association between serum expression of miRNA 661 (miR-661) and ATG-4B mRNA and hepatocellular carcinoma (HCC) based on in silico data analysis followed by clinical validation. Patients & methods
Quantitative reverse-transcriptase real-time PCR was used to examine the expression of miR-661 and ATG-4B mRNA in the sera of HCC patients versus control. Results
The expression of miR-661 and ATG-4B mRNA was positive in 97.14 and 77.14%, respectively, in HCC patients. The survival analysis showed that ATG-4B mRNA was an independent prognostic factor. Conclusion
Our data are the first report of its kind regarding the considerable clinical significance of miR-661 and ATG-4B mRNA in HCC patients.
Future Medicine